Last reviewed · How we verify
Metoclopramide and Ondanteron
This combination blocks dopamine receptors (metoclopramide) to enhance gastric motility and blocks serotonin 5-HT3 receptors (ondansetron) to prevent nausea and vomiting.
This combination blocks dopamine receptors (metoclopramide) to enhance gastric motility and blocks serotonin 5-HT3 receptors (ondansetron) to prevent nausea and vomiting. Used for Nausea and vomiting (likely postoperative or chemotherapy-induced), Gastric dysmotility and delayed gastric emptying.
At a glance
| Generic name | Metoclopramide and Ondanteron |
|---|---|
| Sponsor | Shahid Beheshti University of Medical Sciences |
| Drug class | Antiemetic/Prokinetic combination |
| Target | Dopamine receptors (D2) and 5-HT3 serotonin receptors |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Metoclopramide acts as a dopamine antagonist that increases gastric contractions and accelerates gastric emptying, while ondansetron is a selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract. Together, they provide complementary antiemetic and prokinetic effects for managing nausea, vomiting, and gastric dysmotility.
Approved indications
- Nausea and vomiting (likely postoperative or chemotherapy-induced)
- Gastric dysmotility and delayed gastric emptying
Common side effects
- Headache
- Diarrhea
- Constipation
- Fatigue
- Tardive dyskinesia (metoclopramide)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: